Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation.

Blood
Uday PopatE J Shpall

Abstract

Delayed engraftment is a major limitation of cord blood transplantation (CBT), due in part to a defect in the cord blood (CB) cells' ability to home to the bone marrow. Because this defect appears related to low levels of fucosylation of cell surface molecules that are responsible for binding to P- and E-selectins constitutively expressed by the marrow microvasculature, and thus for marrow homing, we conducted a first-in-humans clinical trial to correct this deficiency. Patients with high-risk hematologic malignancies received myeloablative therapy followed by transplantation with 2 CB units, one of which was treated ex vivo for 30 minutes with the enzyme fucosyltransferase-VI and guanosine diphosphate fucose to enhance the interaction of CD34(+) stem and early progenitor cells with microvessels. The results of enforced fucosylation for 22 patients enrolled in the trial were then compared with those for 31 historical controls who had undergone double unmanipulated CBT. The median time to neutrophil engraftment was 17 days (range, 12-34 days) compared with 26 days (range, 11-48 days) for controls (P = .0023). Platelet engraftment was also improved: median was 35 days (range, 18-100 days) compared with 45 days (range, 27-120 days...Continue Reading

References

Nov 25, 1998·Proceedings of the National Academy of Sciences of the United States of America·P S FrenetteD D Wagner
Nov 26, 1998·The New England Journal of Medicine·P RubinsteinC E Stevens
Jun 16, 2001·The New England Journal of Medicine·M J LaughlinJ Kurtzberg
Jul 20, 2002·Blood·Norbert SchmitzUNKNOWN European Group for Blood and Marrow Transplantation
Dec 17, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Isabel Barao, William J Murphy
Nov 27, 2004·The New England Journal of Medicine·Vanderson RochaUNKNOWN Eurocord-Netcord Registry
Feb 9, 2005·The Journal of Experimental Medicine·Isabelle J Fugier-VivierSuzanne T Ildstad
Dec 13, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Alexandra H FilipovichMary E D Flowers
Apr 28, 2006·The New England Journal of Medicine·Edward A Copelan
Aug 25, 2007·Nature Reviews. Immunology·Klaus LeySussan Nourshargh
Jul 15, 2009·Immunological Reviews·Douglas A CarlowHermann J Ziltener
Nov 3, 2010·Bone Marrow Transplantation·K K Ballen, T R Spitzer
Oct 22, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yi-Bin ChenVincent T Ho
Feb 7, 2012·Experimental Hematology·Simon N RobinsonPatrick A Zweidler-McKay
Feb 23, 2012·Annals of the New York Academy of Sciences·Robert Sackstein
Dec 14, 2012·The New England Journal of Medicine·Marcos de LimaElizabeth J Shpall
Jun 10, 2014·The Journal of Clinical Investigation·Mitchell E HorwitzTony Peled
Jul 24, 2014·The New England Journal of Medicine·Loren GragertMartin Maiers

❮ Previous
Next ❯

Citations

Mar 1, 2016·Frontiers in Medicine·Meral Beksac, Pinar Yurdakul
Dec 5, 2015·Expert Review of Hematology·Frédéric BaronArnon Nagler
Jan 15, 2016·British Journal of Haematology·Karen K Ballen, Hillard Lazarus
Jan 11, 2016·Cell Stem Cell·Sarah Nikiforow, Jerome Ritz
Dec 24, 2015·Frontiers in Medicine·Rohtesh S MehtaElizabeth J Shpall
Dec 18, 2015·Current Hematologic Malignancy Reports·Mitchell E Horwitz
Nov 12, 2015·Current Opinion in Hematology·Jessica L SchwaberLars K Nielsen
Nov 23, 2015·Best Practice & Research. Clinical Haematology·Karen K Ballen
May 15, 2015·Experimental Hematology·Nicolas Pineault, Ahmad Abu-Khader
Apr 24, 2016·Experimental Hematology·Nikoletta PsathaEvangelia Yannaki
May 24, 2016·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Hal E Broxmeyer
Dec 20, 2016·Bone Marrow Transplantation·A Dahlberg, F Milano
Apr 6, 2017·Expert Opinion on Biological Therapy·Sofia BerglundMichael Uhlin
May 10, 2017·The Journal of Clinical Investigation·Jungmin LeeDerrick J Rossi
Dec 16, 2017·Regenerative Medicine·Alain A Vertès
Aug 22, 2018·Regenerative Medicine·Bahareh AbbaspanahSeyed Hadi Mousavi
Sep 22, 2018·Current Opinion in Hematology·Melody Becnel, Elizabeth J Shpall
Sep 21, 2017·F1000Research·Karen Ballen
Jun 13, 2020·Expert Opinion on Biological Therapy·Mattia AlgeriFranco Locatelli
Jul 4, 2020·Stem Cells Translational Medicine·Tamila L Kindwall-Keller, Karen K Ballen
Mar 19, 2016·Molecular Pharmacology·Zahra KazemiEva Zebedin-Brandl
Sep 22, 2018·Frontiers in Oncology·Xingchen PangXiang Li
Dec 7, 2019·Hematology·Annalisa Ruggeri
May 20, 2020·Stem Cell Reviews and Reports·R Alejandro SicaNadim Mahmud

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.